Abstract
A response is provided to a commentary on a recent study examining the impact of low-dose topical application of rapamycin on markers of aging in the skin. The barriers to clinical implementation of therapies targeting the fundamental aging process are discussed, and the topical study is placed in context with the broader effort to develop new therapeutics for age-related disorders.
This is a preview of subscription content, log in via an institution to check access.
References
Bitto A, Lerner C, Torres C, Roell M, Malaguti M, Perez V, et al. Long-term IGF-I exposure decreases autophagy and cell viability. PLoS One. 2010;5:e12592.
Blagosklonny MV. Rapamycin for the aging skin. Aging (Albany NY). 2019;11:12822–6.
Campisi J, Kapahi P, Lithgow GJ, Melov S, Newman JC, Verdin E. From discoveries in ageing research to therapeutics for healthy ageing. Nature. 2019;571:183–92.
Chiao YA, Rabinovitch PS. The aging heart. Cold Spring Harb Perspect Med. 2015;5:a025148.
Chung CL, Lawrence I, Hoffman M, Elgindi D, Nadhan K, Potnis M, et al. Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial. Geroscience. 2019;41:861–9.
Justice JN, Niedernhofer L, Robbins PD, Aroda VR, Espeland MA, Kritchevsky SB, et al. Development of clinical trials to extend healthy lifespan. Cardiovasc Endocrinol Metab. 2018;7:80–3.
Kaeberlein M, Galvan V. Rapamycin and Alzheimer's disease: time for a clinical trial? Sci Transl Med. 2019;11.
Kirkland JL, Tchkonia T. Cellular senescence: a translational perspective. EBioMedicine. 2017;21:21–8.
Koenig MK, Bell CS, Hebert AA, Roberson J, Samuels JA, Slopis JM, et al. Efficacy and safety of topical Rapamycin in patients with facial angiofibromas secondary to tuberous sclerosis complex: the TREATMENT randomized clinical trial. JAMA Dermatol. 2018;154:773–80.
Lawrence J, Nho R. The role of the mammalian target of Rapamycin (mTOR) in pulmonary fibrosis. Int J Mol Sci. 2018;19.
Lerner C, Bitto A, Pulliam D, Nacarelli T, Konigsberg M, Van Remmen H, et al. Reduced mammalian target of rapamycin activity facilitates mitochondrial retrograde signaling and increases life span in normal human fibroblasts. Aging Cell. 2013.
Liao CY, Rikke BA, Johnson TE, Diaz V, Nelson JF. Genetic variation in the murine lifespan response to dietary restriction: from life extension to life shortening. Aging Cell. 2010;9:92–5.
Lichterfeld-Kottner A, El Genedy M, Lahmann N, Blume-Peytavi U, Buscher A, Kottner J. Maintaining skin integrity in the aged: a systematic review. Int J Nurs Stud. 2019;103:103509.
Seymore S.. Patenting new uses for old inventions. Vanderbilt Law Review Forthcoming. 2019
Urfer SR, Kaeberlein TL, Mailheau S, Bergman PJ, Creevy KE, Promislow DEL, et al. A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs. Geroscience. 2017;39:117–27.
Verges B, Cariou B. mTOR inhibitors and diabetes. Diabetes Res Clin Pract. 2015;110:101–8.
Wataya-Kaneda M, Ohno Y, Fujita Y, Yokozeki H, Niizeki H, Ogai M, et al. Sirolimus gel treatment vs placebo for facial angiofibromas in patients with tuberous sclerosis complex: a randomized clinical trial. JAMA Dermatol. 2018;154:781–8.
Wilfond BS, Porter KM, Creevy KE, Kaeberlein M, Promislow D. Research to promote longevity and health span in companion dogs: a pediatric perspective. Am J Bioeth. 2018;18:64–5.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Sell, C. Commentary: rapamycin for the aging skin. GeroScience 42, 813–815 (2020). https://doi.org/10.1007/s11357-020-00184-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11357-020-00184-2